Soleno Therapeutics
SLNO
SLNO was delisted on the 15th of May, 2026.
23 hedge funds and large institutions have $21.8M invested in Soleno Therapeutics in 2023 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 8 reducing their positions, and 1 closing their positions.
209% more capital invested
Capital invested by funds: $7.06M → $21.8M (+$14.7M)
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
21.8% more ownership
Funds ownership: 40.6% → 62.4% (+22%)
10% more funds holding
Funds holding: 21 → 23 (+2)
63% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$9.49M |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$95K |
| 3 |
Osaic Holdings
Scottsdale,
Arizona
|
+$3.44K |
| 4 |
VAG
VisionPoint Advisory Group
Dallas,
Texas
|
+$722 |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$65 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JGC
J. Goldman & Co
New York
|
-$639K |
| 2 |
JP Morgan Chase
New York
|
-$300K |
| 3 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
-$250K |
| 4 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$213K |
| 5 |
CP
Clayton Partners
Berkeley,
California
|
-$199K |
SLNO Hedge Fund Activity: Q2 2023 in Review
23 of the 6,386 institutional investors tracked by Wall St. Rank reported a position in Soleno Therapeutics (SLNO) for Q2 2023, worth a combined $21.8M — up 209% from $7.06M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new SLNO positions and 1 closed out — a net gain of 2 holders — while 3 added to existing stakes and 8 trimmed.
The largest buyer was Perceptive Advisors, opening a new position worth an estimated $9.49M. The largest seller was J. Goldman & Co, cutting an estimated $639K.
- 23 institutional investors held Soleno Therapeutics (SLNO) as of Q2 2023, up from 21 in Q1 2023.
- Funds reported $21.8M of Soleno Therapeutics stock for Q2 2023, up 209% quarter-over-quarter.
- 3 funds opened new Soleno Therapeutics positions in Q2 2023 and 1 closed out, a net change of +2 holders.
- The largest Soleno Therapeutics buyer in Q2 2023 was Perceptive Advisors, an estimated $9.49M added.
- The largest Soleno Therapeutics seller in Q2 2023 was J. Goldman & Co, an estimated $639K sold.
Based on aggregated 13F filings for Q2 2023.